Quick answer
What chemistry decides how a maleimide-linked peptide such as CJC-1295 with DAC should be stored and calculated in the lab? The DAC contains a maleimide group that is reactive toward thiols, and the thiol-maleimide adduct that forms with albumin can later undergo retro-Michael exchange with other thiols or be stabilized by ring opening. Storage, solvent and stock arithmetic therefore matter. Stock concentration is a formula (c = m ÷ V; molar c = m ÷ M ÷ V), and the one published preclinical schedule study specified a defined number of animals, age, duration and interval rather than a general rule. This article gives formulas and published parameters only, with no human amounts. V8 supplies the no-DAC form. For laboratory research use only.
Handling articles for peptides usually collapse everything into "keep it cold". That is adequate for a plain linear peptide, but a peptide that carries a reactive linker has additional chemistry to consider. This article explains what is known about maleimide-thiol chemistry from the conjugation literature, sets out the formula-only arithmetic for stock concentration, and reports what the one published schedule study specified, as a template for what a protocol document should state. It is a research explainer, not a how-to for use in animals or people; not for human or animal consumption. V8 supplies CJC-1295 (No DAC), which has no maleimide; the DAC form is discussed here as the conceptual comparator.
Why the linker changes the handling picture
The DAC in CJC-1295 is a maleimide derivative of lysine (N-epsilon-3-maleimidopropionamide) attached at the C-terminus of the tetrasubstituted hGRF(1-29) chain, designed to bind covalently to the free thiol on Cys34 of serum albumin after it reaches the circulation (Jetté and colleagues, 2005). Maleimides react with thiols by Michael addition, and the same reactivity makes them susceptible to side reactions in the vial: reaction with other thiols, and hydrolysis of the maleimide ring in water. The conjugation literature describes both fates. Baldwin and Kiick (2011) showed that the succinimide thioether formed by thiol addition to N-ethylmaleimide, generally considered stable, undergoes retro and exchange reactions in the presence of other thiol compounds at physiological pH and temperature, with model half-lives of conversion between 20 and 80 hours, and that after ring-opening the product no longer showed retro or exchange reactions. Fontaine and colleagues (2015) noted that the ultimate in vivo fate of maleimide-thiol adducts is disruptive cleavage by thiol exchange or stabilizing ring opening, and that thiol exchange can compromise the efficacy of a conjugate and release the drug. Those papers concern model systems and antibody-drug conjugates, not CJC-1295 specifically, and they should not be read as measurements of that molecule. They do explain why the conjugation chemistry is a variable worth recording.
| Chemical feature | Why it can matter | What a laboratory records |
|---|---|---|
| Free maleimide (before conjugation) | Reactive toward thiols, including those in buffers and media | Solvent and buffer composition; absence or presence of thiols |
| Maleimide ring hydrolysis | Opens the ring and removes thiol reactivity | pH, temperature and time in solution |
| Succinimide thioether (after conjugation) | Can undergo retro-Michael exchange with other thiols | Thiol content of the medium, such as glutathione or cysteine |
| Ring-opened thioether | Reported not to undergo retro or exchange reactions | Time and conditions that favor ring opening |
| Peptide backbone | Oxidation, deamidation, aggregation in solution | pH, light, temperature, number of freeze–thaw cycles |
General solution stability does not disappear
Whatever the linker, the peptide chain follows general stability rules. Reviews of protein and peptide stability emphasize that chemical routes (oxidation, deamidation, hydrolysis) and physical routes (aggregation, adsorption) depend on pH, temperature, ionic strength and excipients (Manning and colleagues, 2010; Wang, 1999). Peptides with oxidation-prone residues are protected from light and oxygen, and the native sequence carries a methionine at position 27 (Guillemin and colleagues, 1982), a residue type that is oxidation-prone, and the modified analog differs at that position. Adsorption to plastic and glass is a separate source of loss: peptide recovery varies unpredictably with the container surface, and surface choice and added carrier protein changed recovery in a radiolabeled-peptide study (Goebel-Stengel and colleagues, 2011), which is why container choice and few transfers are standard practice. The reasoning for aliquoting and storage temperature is collected in storing research peptides and how long reconstituted peptides last. The product page for the no-DAC reagent states storage at 2–8 °C, −20 °C for long term, protected from heat, moisture and light, in a sealed clear glass research vial; that statement is specific to the supplied product.
Stock arithmetic, formulas only
All stock calculations reduce to relationships between mass, molar mass and volume. Write the symbols and units before substituting values.
| Quantity | Formula | Unit note |
|---|---|---|
| Mass concentration | cm = m ÷ V | mg per mL when m is in mg and V in mL |
| Amount of substance | n = m ÷ M | mg ÷ (g/mol) gives mmol |
| Molar concentration | c = m ÷ (M × V) | mg, g/mol and mL give mmol/mL, which equals mol/L |
| Dilution | C1V1 = C2V2 | Keep units consistent on both sides |
| Net peptide content correction | mnet = mgross × f | f is the fraction of peptide in the powder, from the analytical record |
A mass-based stock is easy to check against the vial label, but molar comparisons between forms require the molar mass of each, and a conjugate and its unconjugated precursor have different molar masses. For the albumin conjugate itself the relevant mass includes albumin (about 66.5 kDa for human serum albumin), so a molar concentration of "conjugate" and a molar concentration of "peptide" are only equal when every peptide is bound. This is a reason to define the analyte in the protocol. The reconstitution calculator does the arithmetic, and the calculator guide explains it step by step.
What the published schedule study specified
The knockout mouse study that tested interval is the clearest example of how a published protocol defined its variables. Its abstract specifies the model (GHRH-knockout mice), the age at start (1 week), the duration (5 weeks), the intervals (24, 48 and 72 hours), the amount per administration (2 µg of CJC-1295) and the controls (placebo-exposed knockout mice and mice heterozygous for the knockout allele) (Alba and colleagues, 2006). Those are reported study parameters, and they are listed here to show what a protocol must state, not as recommendations. The rat study that introduced the compound, in turn, specified male Sprague Dawley rats, subcutaneous administration and a 2-hour GH area-under-the-curve window (Jetté and colleagues, 2005). In each case the schedule follows from a scientific question and a defined model.
| Protocol element | Mouse interval study | Rat introduction study |
|---|---|---|
| Species and strain | GHRH-knockout mice, heterozygous controls | Male Sprague Dawley rats |
| Age or stage | Exposure from 1 week of age | Normal adult male |
| Route | Stated in the full paper | Subcutaneous |
| Schedule variable | 24, 48 and 72 h intervals | Single administration, 2-h and longer sampling |
| Duration | 5 weeks | Up to beyond 72 h for plasma detection |
| Comparators | Placebo-exposed knockout; heterozygous mice | hGRF(1-29) |
| Primary endpoints | Body weight, length, composition, pituitary RNA | GH area under the curve, plasma persistence |
Worked unit check
As a pure arithmetic illustration with the no-DAC reagent, whose product page lists 5 mg and 10 mg vials and whose research guide gives an average mass of about 3,367.9 g/mol: a 5 mg vial holds 5 ÷ 3,367.9 = 1.485 µmol. Dissolved in V mL, that is 1,485 ÷ V µM, so 2 mL gives roughly 742 µM and a 1:100 dilution of that stock gives roughly 7.4 µM. The same sums for a 10 mg vial double each figure. For a conjugate the numbers would be built from the conjugate’s own molar mass, and the units would need to say whether concentration refers to peptide or to complex. The point of working the units each time is that a transcription slip between mg, µg and mL is the most common source of a ten-fold error, and a short written calculation in the notebook, checked by a second person where possible, catches it.
It also helps to decide the order of operations in advance. Compute the vial content from the labeled mass and net peptide content, choose the stock volume from the smallest dilution step needed, compute each working concentration from the stock rather than from a previous working solution, and record every volume actually pipetted. Pipetting error accumulates through serial dilutions, so fewer steps from a well-characterized stock give a more defensible final concentration than many steps from an uncertain one.
A protocol-document checklist
- Test article identity. Name, lot, labeled purity and the analytical record, with the form (with or without linker) stated explicitly. See how to read a COA and the COA library.
- Solvent and buffer composition. Include any thiol-containing components, since thiols can react with a maleimide.
- Preparation and storage log. Date prepared, temperature history, freeze–thaw count, container material.
- Analyte definition. Peptide, conjugate or bioactivity, as discussed above.
- Schedule justification. The scientific reason for each interval, as in the interval study.
- Controls. Vehicle, comparator form and, where relevant, a genotype control.
- Reporting. Follow a recognized reporting guideline for animal studies and declare ethics approval.
What this article does not provide
It does not recommend an amount, a schedule or a route for any animal, and it does not describe use outside a laboratory. The published numbers above are quoted so that a reader can see what the authors specified; each investigator is responsible for the design and approval of their own work. For further reading on the form that V8 supplies, see the CJC-1295 (No DAC) research guide, the DAC versus no-DAC comparison and the purity testing guide. The full range is in the catalog.
For laboratory research use only.
Frequently asked questions
Why does a maleimide linker change handling considerations?
A maleimide reacts with thiols and can hydrolyze in water, so solvent composition, pH, temperature and time in solution are chemical variables, not just physical ones.
What did Baldwin and Kiick report about maleimide-thiol adducts?
That the succinimide thioether can undergo retro and exchange reactions with other thiols at physiological pH and temperature, with model conversion half-lives of 20 to 80 hours, and that ring-opened products no longer did.
Do those chemistry papers measure CJC-1295?
No. They concern model compounds and antibody-drug conjugates, and they explain why the linkage chemistry is worth recording.
How is a stock concentration calculated?
Mass concentration is m ÷ V. Molar concentration is m ÷ (M × V), with units kept consistent. The reconstitution calculator performs this arithmetic.
Why do conjugate and peptide molar concentrations differ?
A conjugate includes albumin, so its molar mass is far larger. The two are equal only if every peptide molecule is bound.
What did the mouse interval study specify?
GHRH-knockout mice exposed from 1 week of age for 5 weeks at 24-, 48- and 72-hour intervals with 2 µg of CJC-1295 per administration, plus placebo and heterozygous controls.
Is that a recommendation?
No. It is a published parameter list shown as an example of what a protocol must state.
What storage does the no-DAC product page state?
2–8 °C, −20 °C for long term, protected from heat, moisture and light, in a sealed clear glass research vial.
Does V8 sell the DAC form?
No. The catalog lists the no-DAC form.
Why record the freeze–thaw count?
Freeze–thaw cycles can change aggregation and adsorption behavior, and the count helps explain differences between experiments.
Related reading: CJC-1295 DAC Safety Profile: Preclinical Tolerability, CJC-1295 DAC vs No DAC: Which Form Fits the Assay?, CJC-1295 DAC History: From GHRH to Albumin Conjugate.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem. 2011;22(10):1946-1953. doi:10.1021/bc200148v
- Fontaine SD, Reid R, Robinson L, Ashley GW, Santi DV. Long-term stabilization of maleimide-thiol conjugates. Bioconjug Chem. 2015;26(1):145-152. doi:10.1021/bc5005262
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
